Revance Investors Ink $17M Deal In Take-Private Offer Suit

By Sydney Price · March 23, 2026, 7:51 PM EDT

Dermal fillers company Revance Therapeutics Inc. and two of its executives have agreed to a $17 million settlement to end claims the company hurt investors after the value of a take-private...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

In re Revance Therapeutics, Inc. Securities Litigation

Case Number

Court

Tennessee Middle

Nature of Suit

Securities/Commodities

Date Filed

January 03, 2025

Recent Articles By Sydney

March 20, 2026
Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit
March 18, 2026
SelectQuote Looks To Escape Investors' Kickback Probe Suit
March 05, 2026
Drugmaker Aquestive Hit With Suit Over FDA Approval Delay
March 03, 2026
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit
February 03, 2026
Masimo Investors' $34M Deal In Revenue Suit Gets Initial OK
January 30, 2026
SelectQuote Execs Face Investor Suit Over Kickback Probe
January 16, 2026
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings
January 16, 2026
Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit
January 09, 2026
Ex-Doximity Exec Cops To $2.5M Insider Trading Scheme
January 08, 2026
Ardent Health Investors Sue Over Revenue Accounting Issues